Share this article and save a life!
This AI doesn’t just flag findings, it writes the entire radiology report.
On April 16th, the FDA granted Breakthrough Device Designation to Cognita CXR, marking a pivotal shift in how we think about AI in radiology.
Here’s what makes this different:
Traditional AI tools spot individual problems: a lung nodule here, a fracture there. They’re basically digital highlighters.
Cognita CXR? It analyzes the entire chest X-ray and drafts a comprehensive preliminary report. Not fragments. Not alerts. Complete findings, ready for radiologist review.
The validation numbers caught my attention:
• 16-65% improvement in detecting significant findings
• 18% boost in interpretation efficiency
• Licensed radiologists maintain full control and final say
Think about what this means for patient care.
We’re facing the third consecutive year where workforce shortages are radiology’s biggest threat. Meanwhile, imaging volumes keep climbing. Something has to give.
But here’s my question: Are we ready for AI that doesn’t just assist but actually authors the first draft?
Some radiologists will see this as a threat. Others will embrace it as liberation from the mundane, letting them focus on complex cases and patient interaction.
The FDA’s Breakthrough Device Designation signals urgency. They’re fast-tracking this because the capacity crisis is real.
What strikes me most: We’ve crossed from AI as a second opinion to AI as the first author. That’s not iteration, that’s transformation.
The radiologist becomes an editor, not just a reader. Quality controller, not just interpreter.
Is this the future we want? I think it’s the future we need.
♻️ Repost if radiology AI should draft reports, not just flag findings.
👉 Follow me, Jonathan Govette, for daily, real-time updates on healthcare technology and business news. LinkedIn Profile: https://www.linkedin.com/in/jonathangovette/
Share this article and save a life!
Author:
Jonathan Govette is a seasoned healthcare and technology executive with more than two decades of experience building, scaling, and advising digital health companies. He is the Co-Founder and CEO of Oatmeal Health, an AI-driven Lung Cancer Screening and Diagnostics company focused on expanding access to early detection for underrepresented populations, particularly patients served by Federally Qualified Health Centers and value-based health plans.
With a background in engineering, product development, and strategic partnerships, Jonathan has founded and led multiple health technology ventures across clinical care delivery, regulated medical software, and AI-enabled diagnostics. His work sits at the intersection of medicine, technology, and health equity, with a consistent focus on translating complex clinical problems into scalable, real-world solutions.
Jonathan has spent much of his professional life dedicated to improving outcomes for marginalized and underserved communities. He has designed and implemented frameworks that align clinical quality, reimbursement, and technology to sustainably advance health equity at scale. This mission is deeply personal and informs his leadership philosophy and long-term vision for healthcare transformation.
In addition to his operating experience, Jonathan is an author and long-time writer in the healthcare domain, with over 20 years of published work covering digital health, medical innovation, and healthcare systems. He is a frequent mentor to early-stage founders and regularly advises startups on product strategy, partnerships, and go-to-market execution in regulated healthcare environments.
Before entering industry full-time, Jonathan nearly pursued a career in medicine with an early path toward cardiothoracic surgery, an experience that continues to shape his clinical perspective and respect for frontline care delivery.
CEO | Oatmeal Health | AI Lung Cancer Startup | Engineer | Writer | Almost Became a Doctor (Cardiac Thoracic Surgeon) | 3x Health Tech Founder | Startup Mentor | Follow to share what I’ve learned along the way.
